RU2005134670A - Производные имидазола для лечения аллергических и гиперпролиферативных нарушений - Google Patents
Производные имидазола для лечения аллергических и гиперпролиферативных нарушений Download PDFInfo
- Publication number
- RU2005134670A RU2005134670A RU2005134670/04A RU2005134670A RU2005134670A RU 2005134670 A RU2005134670 A RU 2005134670A RU 2005134670/04 A RU2005134670/04 A RU 2005134670/04A RU 2005134670 A RU2005134670 A RU 2005134670A RU 2005134670 A RU2005134670 A RU 2005134670A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- alkyl
- group
- formula
- hydrogen
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 70
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 239000001257 hydrogen Substances 0.000 claims 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 35
- 125000000623 heterocyclic group Chemical group 0.000 claims 31
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 125000005842 heteroatom Chemical group 0.000 claims 28
- 125000001624 naphthyl group Chemical group 0.000 claims 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000000547 substituted alkyl group Chemical group 0.000 claims 28
- 125000001931 aliphatic group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000003367 polycyclic group Chemical group 0.000 claims 15
- -1 C 1 -C 5 alkyl Chemical group 0.000 claims 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 239000001301 oxygen Substances 0.000 claims 14
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 239000011593 sulfur Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- JBNVRLURWDLBOD-UHFFFAOYSA-N 2-nitrobenzenecarboximidamide Chemical class NC(=N)C1=CC=CC=C1[N+]([O-])=O JBNVRLURWDLBOD-UHFFFAOYSA-N 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000007062 hydrolysis Effects 0.000 claims 5
- 238000006460 hydrolysis reaction Methods 0.000 claims 5
- SWBDKCMOLSUXRH-UHFFFAOYSA-N 2-nitrobenzonitrile Chemical class [O-][N+](=O)C1=CC=CC=C1C#N SWBDKCMOLSUXRH-UHFFFAOYSA-N 0.000 claims 4
- 230000009435 amidation Effects 0.000 claims 4
- 238000007112 amidation reaction Methods 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- 230000010933 acylation Effects 0.000 claims 3
- 238000005917 acylation reaction Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000002574 poison Substances 0.000 claims 3
- 231100000614 poison Toxicity 0.000 claims 3
- 238000011084 recovery Methods 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 238000005576 amination reaction Methods 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 150000003919 1,2,3-triazines Chemical class 0.000 claims 1
- 150000003920 1,2,4-triazines Chemical class 0.000 claims 1
- 150000000182 1,3,5-triazines Chemical class 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001532 anti-fungicidal effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 150000008371 chromenes Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 150000001907 coumarones Chemical class 0.000 claims 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002240 furans Chemical class 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 150000002461 imidazolidines Chemical class 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 150000002537 isoquinolines Chemical class 0.000 claims 1
- 150000003854 isothiazoles Chemical class 0.000 claims 1
- 150000002545 isoxazoles Chemical class 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 1
- 150000002916 oxazoles Chemical class 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 claims 1
- 150000003216 pyrazines Chemical class 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 claims 1
- 150000003218 pyrazolidines Chemical class 0.000 claims 1
- 150000004892 pyridazines Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 150000003235 pyrrolidines Chemical class 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
- 150000004886 thiomorpholines Chemical class 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003577 thiophenes Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46209003P | 2003-04-10 | 2003-04-10 | |
| US60/462.090 | 2003-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005134670A true RU2005134670A (ru) | 2006-06-10 |
Family
ID=33299906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005134670/04A RU2005134670A (ru) | 2003-04-10 | 2004-04-09 | Производные имидазола для лечения аллергических и гиперпролиферативных нарушений |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040229927A1 (enExample) |
| EP (1) | EP1613310A1 (enExample) |
| JP (1) | JP2006522820A (enExample) |
| KR (1) | KR20050120711A (enExample) |
| CN (1) | CN1826111A (enExample) |
| AR (1) | AR045886A1 (enExample) |
| AU (1) | AU2004229466A1 (enExample) |
| BR (1) | BRPI0409097A (enExample) |
| CA (1) | CA2521841A1 (enExample) |
| MX (1) | MXJL05000041A (enExample) |
| PL (1) | PL378919A1 (enExample) |
| RU (1) | RU2005134670A (enExample) |
| TW (1) | TW200503695A (enExample) |
| WO (1) | WO2004091610A1 (enExample) |
| ZA (1) | ZA200508108B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2506260C2 (ru) * | 2008-06-25 | 2014-02-10 | Энвиво Фармасьютикалз, Инк. | 1,2-дизамещенные гетероциклические соединения |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| DE60221804T2 (de) * | 2001-03-12 | 2008-05-15 | Avanir Pharmaceuticals, San Diego | Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US20050256179A1 (en) * | 2003-08-08 | 2005-11-17 | Sircar Jagadish C | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| CN101022728B (zh) * | 2004-03-25 | 2012-08-08 | 詹森药业有限公司 | 咪唑化合物 |
| EA200802058A1 (ru) * | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| PE20080948A1 (es) | 2006-07-25 | 2008-09-10 | Irm Llc | Derivados de imidazol como moduladores de la senda de hedgehog |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| DK2959900T3 (en) | 2008-06-16 | 2017-06-26 | Univ Tennessee Res Found | CONNECTION TO TREATMENT OF CANCER |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| EP2542081A4 (en) * | 2010-03-01 | 2013-07-31 | Gtx Inc | COMPOSITIONS FOR CANCER TREATMENT |
| DK3066080T5 (en) * | 2013-11-05 | 2018-09-17 | Bayer Cropscience Ag | SUBSTITUTED BENZAMIDES FOR TREATMENT OF ARTHROPODS |
| WO2016105491A1 (en) | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| WO2017190086A1 (en) | 2016-04-29 | 2017-11-02 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| WO2018049080A1 (en) | 2016-09-07 | 2018-03-15 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| EP3573957B1 (en) * | 2017-01-24 | 2023-04-26 | Rivara, Mirko | Compositions and methods for blocking sodium channels |
| CN108191667B (zh) * | 2018-01-04 | 2021-03-26 | 利尔化学股份有限公司 | 2-硝基-4-三氟甲基苯甲酸甲酯的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206257A (en) * | 1987-03-05 | 1993-04-27 | May & Baker Limited | Pesticidal method using 2-phenylimidazole derivatives |
| JP2630432B2 (ja) * | 1987-08-24 | 1997-07-16 | コニカ株式会社 | 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料 |
| JPH01224759A (ja) * | 1988-03-03 | 1989-09-07 | Konica Corp | 新規なシアンカプラーを含有するハロゲン化銀写真感光材料 |
| JPH01225949A (ja) * | 1988-03-04 | 1989-09-08 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH01262546A (ja) * | 1988-04-13 | 1989-10-19 | Konica Corp | 新規なシアンカプラーを含有するハロゲン化銀写真感光材料 |
| JPH0361946A (ja) * | 1989-07-29 | 1991-03-18 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| JPH03245140A (ja) * | 1990-02-23 | 1991-10-31 | Konica Corp | 新規なシアンカプラーを含有するハロゲン化銀写真感光材料 |
| US5712392A (en) * | 1990-12-28 | 1998-01-27 | Neurogen Corporation | Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands |
| JPH09304897A (ja) * | 1996-05-10 | 1997-11-28 | Konica Corp | 新規なシアンカプラーを含有するハロゲン化銀写真感光材料 |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| CA2232467A1 (en) * | 1997-03-20 | 1998-09-20 | Richard A. Glennon | Imidazoles with serotonin receptor binding activity |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
-
2004
- 2004-04-09 WO PCT/US2004/011010 patent/WO2004091610A1/en not_active Ceased
- 2004-04-09 MX MXJL05000041A patent/MXJL05000041A/es unknown
- 2004-04-09 AU AU2004229466A patent/AU2004229466A1/en not_active Abandoned
- 2004-04-09 RU RU2005134670/04A patent/RU2005134670A/ru not_active Application Discontinuation
- 2004-04-09 CA CA002521841A patent/CA2521841A1/en not_active Abandoned
- 2004-04-09 BR BRPI0409097-7A patent/BRPI0409097A/pt not_active IP Right Cessation
- 2004-04-09 US US10/821,667 patent/US20040229927A1/en not_active Abandoned
- 2004-04-09 CN CNA2004800162918A patent/CN1826111A/zh active Pending
- 2004-04-09 KR KR1020057019229A patent/KR20050120711A/ko not_active Withdrawn
- 2004-04-09 EP EP04759360A patent/EP1613310A1/en not_active Withdrawn
- 2004-04-09 JP JP2006509872A patent/JP2006522820A/ja active Pending
- 2004-04-09 PL PL378919A patent/PL378919A1/pl not_active Application Discontinuation
- 2004-04-12 AR ARP040101207A patent/AR045886A1/es not_active Application Discontinuation
- 2004-04-12 TW TW093110069A patent/TW200503695A/zh unknown
-
2005
- 2005-10-07 ZA ZA200508108A patent/ZA200508108B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2506260C2 (ru) * | 2008-06-25 | 2014-02-10 | Энвиво Фармасьютикалз, Инк. | 1,2-дизамещенные гетероциклические соединения |
Also Published As
| Publication number | Publication date |
|---|---|
| AR045886A1 (es) | 2005-11-16 |
| TW200503695A (en) | 2005-02-01 |
| ZA200508108B (en) | 2007-03-28 |
| WO2004091610A1 (en) | 2004-10-28 |
| BRPI0409097A (pt) | 2006-04-11 |
| EP1613310A1 (en) | 2006-01-11 |
| CN1826111A (zh) | 2006-08-30 |
| CA2521841A1 (en) | 2004-10-28 |
| PL378919A1 (pl) | 2006-06-12 |
| AU2004229466A1 (en) | 2004-10-28 |
| MXJL05000041A (es) | 2005-12-22 |
| KR20050120711A (ko) | 2005-12-22 |
| US20040229927A1 (en) | 2004-11-18 |
| JP2006522820A (ja) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005134670A (ru) | Производные имидазола для лечения аллергических и гиперпролиферативных нарушений | |
| RU2003127367A (ru) | Бензимидазоловые соединения для модулирования ige и ингибирования клеточной пролиферации | |
| JP2006503048A5 (enExample) | ||
| JP2004528304A5 (enExample) | ||
| JP2006512293A5 (enExample) | ||
| AU696390B2 (en) | Quinolones and their therapeutic use | |
| RU2005109911A (ru) | Соединения фенил-аза-бензимидазола для модуляции ige и подавления разрастания клеток | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| DE69408750T2 (de) | 4-Aminopyrimidin Derivate | |
| RU2330019C2 (ru) | Производные пиперидина, способ их получения, фармацевтическая композиция на их основе и способ лечения хемокин-опосредованного болезненного состояния с их использованием | |
| JP2005538100A5 (enExample) | ||
| RU2005109912A (ru) | Соединения фенил-индола для модуляции ige и подавления разрастания клеток | |
| PL128409B1 (en) | Process for preparing novel derivatives of piperidine | |
| RU2005134652A (ru) | Конденсированные n-гетероциклические соединения и их применение в качестве антагонистов рецепторов crf | |
| PE20011334A1 (es) | Compuestos y composiciones de indazol de formula (i) | |
| JP2006522820A5 (enExample) | ||
| CA2652834A1 (en) | Substituted arylimidazolones and -triazolones and the use thereof | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| US20110183969A1 (en) | Antifungal combination therapy | |
| RU2003129638A (ru) | Новые соединения | |
| RU2007119373A (ru) | Фармацевтические соединения | |
| CA2361057A1 (en) | Quinoline derivatives and quinazoline derivatives | |
| DE60117847T2 (de) | Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate | |
| KR880009019A (ko) | 트리시클릭벤즈이미다졸, 이들의 제조방법 및 이들을 함유하는 약리학적 조성물 | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080306 |